CA3015512C - Treatment of neurodegenerative eye disease using pridopidine - Google Patents
Treatment of neurodegenerative eye disease using pridopidine Download PDFInfo
- Publication number
- CA3015512C CA3015512C CA3015512A CA3015512A CA3015512C CA 3015512 C CA3015512 C CA 3015512C CA 3015512 A CA3015512 A CA 3015512A CA 3015512 A CA3015512 A CA 3015512A CA 3015512 C CA3015512 C CA 3015512C
- Authority
- CA
- Canada
- Prior art keywords
- pridopidine
- subject
- eye
- treatment
- pharmaceutically acceptable
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/451—Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Ophthalmology & Optometry (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medical Preparation Storing Or Oral Administration Devices (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662299290P | 2016-02-24 | 2016-02-24 | |
| US62/299,290 | 2016-02-24 | ||
| PCT/US2017/019266 WO2017147366A1 (en) | 2016-02-24 | 2017-02-24 | Treatment of neurodegenerative eye disease using pridopidine |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA3015512A1 CA3015512A1 (en) | 2017-08-31 |
| CA3015512C true CA3015512C (en) | 2024-01-16 |
Family
ID=59686581
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3015512A Active CA3015512C (en) | 2016-02-24 | 2017-02-24 | Treatment of neurodegenerative eye disease using pridopidine |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US11738012B2 (enExample) |
| EP (1) | EP3419622B1 (enExample) |
| JP (1) | JP7034488B2 (enExample) |
| AU (1) | AU2017223838B2 (enExample) |
| CA (1) | CA3015512C (enExample) |
| DK (1) | DK3419622T3 (enExample) |
| ES (1) | ES2979123T3 (enExample) |
| HU (1) | HUE066769T2 (enExample) |
| PL (1) | PL3419622T3 (enExample) |
| WO (1) | WO2017147366A1 (enExample) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ608120A (en) | 2010-09-03 | 2014-12-24 | Ivax Int Gmbh | Deuterated analogs of pridopidine useful as dopaminergic stabilizers |
| US11090297B2 (en) | 2013-06-21 | 2021-08-17 | Prilenia Neurotherapeutics Ltd. | Pridopidine for treating huntington's disease |
| US11471449B2 (en) | 2015-02-25 | 2022-10-18 | Prilenia Neurotherapeutics Ltd. | Use of pridopidine to improve cognitive function and for treating Alzheimer's disease |
| US20220062255A1 (en) * | 2016-02-24 | 2022-03-03 | Prilenia Neurotherapeutics Ltd. | Treatment of neurodegenerative eye disease using pridopidine |
| IL311081A (en) | 2016-08-24 | 2024-04-01 | Prilenia Neurotherapeutics Ltd | Use of pyridofidine to treat functional decline |
| CN110012661A (zh) | 2016-08-24 | 2019-07-12 | 普瑞尼亚医疗发展有限公司 | 普利多匹定用于治疗肌张力障碍的用途 |
| US12102627B2 (en) | 2016-09-16 | 2024-10-01 | Prilenia Neurotherapeutics Ltd. | Use of pridopidine for treating rett syndrome |
| US12036213B2 (en) | 2017-09-08 | 2024-07-16 | Prilenia Neurotherapeutics Ltd. | Pridopidine for treating drug induced dyskinesias |
| CA3075020C (en) | 2017-09-08 | 2021-12-07 | Prilenia Neurotherapeutics Ltd. | Pridopidine for treating drug induced dyskinesias |
| JP7585561B2 (ja) | 2019-02-04 | 2024-11-19 | プリレニア ニューロセラピューティクス リミテッド | パーキンソン病およびパーキンソニズムに関連する他の疾患のための低用量プリドピジン |
| AU2020243692B2 (en) * | 2019-03-15 | 2023-03-02 | Prilenia Neurotherapeutics Ltd. | Treatment of mitochondrial associated diseases and disorders, including symptoms thereof using pridopidine |
| CN116472043A (zh) | 2020-10-20 | 2023-07-21 | 普瑞尼亚神经治疗有限公司 | 普利多匹定和类似物用于治疗焦虑和抑郁的用途 |
| WO2023062632A1 (en) * | 2021-10-11 | 2023-04-20 | Prilenia Neurotherapeutics Ltd. | Pridopidine and analogs thereof for the treatment of neurodegenerative eye disease |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| USRE46117E1 (en) | 1999-12-22 | 2016-08-23 | Teva Pharmaceuticals International Gmbh | Modulators of dopamine neurotransmission |
| SE9904724D0 (sv) | 1999-12-22 | 1999-12-22 | Carlsson A Research Ab | New modulators of dopamine neurotransmission I |
| IL134241A (en) * | 2000-01-27 | 2006-06-11 | Finetech Pharmaceutical Ltd | Process for the preparation of latanoprost |
| WO2004103263A2 (en) * | 2003-05-22 | 2004-12-02 | Yeda Research And Development Co. Ltd. | Dopamine and agonists and antagonists thereof for treatment of neurodegenerative diseases |
| SE0401465D0 (sv) | 2004-06-08 | 2004-06-08 | Carlsson A Research Ab | New substituted piperdines as modulators of dopamine neurotransmission |
| ES2659577T3 (es) | 2004-10-13 | 2018-03-16 | Teva Pharmaceuticals International Gmbh | Proceso para la síntesis de 4-(3-metanosulfonilfenil)-1-N-propil-piperidina |
| MX2009011020A (es) | 2007-04-12 | 2009-10-30 | Nsab Af Neurosearch Sweden Ab | Derivados de n-oxido y/o di-n-oxido de los estabilizadores/modulad ores del receptor de dopamina que exhiben perfiles mejorados de los efectos secundarios cardiovasculares. |
| EP2170343A1 (en) | 2007-05-31 | 2010-04-07 | Joseph Weinstock | Treatment of age-related macular degeneration |
| US20090062400A1 (en) | 2007-09-05 | 2009-03-05 | Laurence Oron | Method of treating glaucoma using rasagiline |
| US20110206782A1 (en) * | 2010-02-24 | 2011-08-25 | Auspex Pharmaceuticals, Inc. | Piperidine modulators of dopamine receptor |
| WO2011107583A1 (en) * | 2010-03-04 | 2011-09-09 | Nsab, Filial Af Neurosearch Sweden Ab, Sverige | Substituted 4-phenyl-n-alkyl-piperidines for preventing onset or slowing progression of neurodegenerative disorders |
| NZ608120A (en) | 2010-09-03 | 2014-12-24 | Ivax Int Gmbh | Deuterated analogs of pridopidine useful as dopaminergic stabilizers |
| MX343620B (es) | 2011-09-07 | 2016-11-11 | Teva Pharmaceuticals Int Gmbh | Forma polimorfica de clorhidrato de pridopidina. |
| EP2787997A4 (en) | 2011-12-08 | 2015-05-27 | Ivax Int Gmbh | HYDROBROMIDE SALT OF PRIDOPIDINE |
| BR112014024672A8 (pt) | 2012-04-04 | 2018-04-03 | Ivax Int Gmbh | Composições farmacêuticas para terapia de combinação |
| MX2015003812A (es) | 2012-09-27 | 2015-07-17 | Teva Pharma | Combinacion de rasagilina y pridopidina para tratar trastornos neurodegenerativos, en particular enfermedad de huntington. |
| CA2913781C (en) | 2013-06-21 | 2022-05-10 | Teva Pharmaceutical Industries Ltd. | Use of pridopidine for treating huntington's disease |
| US11090297B2 (en) | 2013-06-21 | 2021-08-17 | Prilenia Neurotherapeutics Ltd. | Pridopidine for treating huntington's disease |
| CA2937243C (en) | 2014-01-22 | 2023-07-18 | Teva Pharmaceuticals International Gmbh | Modified release formulations of pridopidine |
| TW201613859A (en) | 2014-06-30 | 2016-04-16 | Teva Pharma | Analogs of PRIDOPIDINE, their preparation and use |
| WO2016106142A1 (en) | 2014-12-22 | 2016-06-30 | Teva Pharmaceuticals International Gmbh | L-tartrate salt of pridopidine |
| WO2016138135A1 (en) | 2015-02-25 | 2016-09-01 | Teva Pharmaceuticals International Gmbh | Sigma-1 receptor modulators for treating huntington's disease |
| EP3854785A1 (en) * | 2015-02-25 | 2021-07-28 | Prilenia Neurotherapeutics Ltd. | Use of pridopidine to treat depression or anxiety |
| AR105434A1 (es) | 2015-07-22 | 2017-10-04 | Teva Pharmaceuticals Int Gmbh | Proceso para preparar pridopidina |
| EP3324967A4 (en) | 2015-07-22 | 2019-03-20 | Prilenia Therapeutics Development Ltd. | PRIDOPIDINE-BASED FORMULATIONS AND USE OF THE SAME |
| KR20200031446A (ko) | 2018-09-14 | 2020-03-24 | 삼성전자주식회사 | 무선 통신 시스템에서 pdcch 모니터링 방법 및 장치 |
-
2017
- 2017-02-24 EP EP17757261.7A patent/EP3419622B1/en active Active
- 2017-02-24 PL PL17757261.7T patent/PL3419622T3/pl unknown
- 2017-02-24 AU AU2017223838A patent/AU2017223838B2/en active Active
- 2017-02-24 JP JP2018544853A patent/JP7034488B2/ja active Active
- 2017-02-24 HU HUE17757261A patent/HUE066769T2/hu unknown
- 2017-02-24 DK DK17757261.7T patent/DK3419622T3/da active
- 2017-02-24 US US16/078,929 patent/US11738012B2/en active Active
- 2017-02-24 WO PCT/US2017/019266 patent/WO2017147366A1/en not_active Ceased
- 2017-02-24 CA CA3015512A patent/CA3015512C/en active Active
- 2017-02-24 ES ES17757261T patent/ES2979123T3/es active Active
Also Published As
| Publication number | Publication date |
|---|---|
| EP3419622B1 (en) | 2024-03-06 |
| ES2979123T3 (es) | 2024-09-24 |
| DK3419622T3 (da) | 2024-06-03 |
| EP3419622A4 (en) | 2019-07-10 |
| PL3419622T3 (pl) | 2024-07-08 |
| JP7034488B2 (ja) | 2022-03-14 |
| CA3015512A1 (en) | 2017-08-31 |
| AU2017223838B2 (en) | 2022-09-29 |
| HUE066769T2 (hu) | 2024-09-28 |
| AU2017223838A1 (en) | 2018-09-06 |
| WO2017147366A1 (en) | 2017-08-31 |
| US11738012B2 (en) | 2023-08-29 |
| US20190046516A1 (en) | 2019-02-14 |
| EP3419622A1 (en) | 2019-01-02 |
| JP2019507758A (ja) | 2019-03-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2017223838B2 (en) | Treatment of neurodegenerative eye disease using pridopidine | |
| EP3886858B1 (en) | Compounds for treatment of eye diseases associated with excessive vascularisation | |
| US11654140B2 (en) | Treatment of ocular inflammatory diseases using laquinimod | |
| US20180140593A1 (en) | Treatment of Glaucoma Using Laquinimod | |
| US20220062255A1 (en) | Treatment of neurodegenerative eye disease using pridopidine | |
| US20240261273A1 (en) | Pridopidine and analogs thereof for the treatment of neurodegenerative eye disease | |
| JP2019070026A (ja) | 外用剤 | |
| AU2025217391A1 (en) | Pridopidine and analogs thereof for the treatment of neurodegenerative eye disease | |
| Williams et al. | Drug Induced Maculopathies | |
| HK40061312B (en) | Compounds for treatment of eye diseases associated with excessive vascularisation | |
| WO2026043737A1 (en) | Methods and compositions for preserving the retinal outer nuclear layer (onl), photoreceptors, and retinal thickness | |
| JP2024032794A (ja) | 網膜の神経細胞の保護剤 | |
| WO2020166679A1 (ja) | 眼圧下降用医薬組成物 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20211220 |
|
| MPN | Maintenance fee for patent paid |
Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 8TH ANNIV.) - STANDARD Year of fee payment: 8 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20241206 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT Effective date: 20241206 Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20241206 |
|
| MPN | Maintenance fee for patent paid |
Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 9TH ANNIV.) - STANDARD Year of fee payment: 9 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20251202 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20251202 |